Li CX, Liang S, Gao L, et al
Higher discontinuation rates and lower maintenance doses compared to trials
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
By the 24-week mark, levels decreased by 2.02% (22.07 mmol/mol), and by 2.16% (23.59 mmol/mol) at 36 weeks, compared to no significant changes in the control group
Missbruksrelaterade ddsfall halverades och sjlvmordstankar eller sjlvmordsfrsk minskade med 25 procent
Your focus should be on building a comprehensive treatment plan that includes not just the medication but also nutritional support, physical activity modifications, and monitoring for the more significant side effects that can accompany larger doses